MN-001 – 500 µg

Brand:
Cayman
CAS:
125961-82-2
Storage:
-20
UN-No:
Non-Hazardous - /

MN-001 is an orally bioavailable anti-inflammatory agent whose mechanisms of action include inhibition of eosinophil migration, antagonism of leukotriene receptors, and inhibition of phosphodiesterases 3 and 4.{33367} Other mechanisms of action described for MN-001 include the inhibition of 5-lipoxygenase, phospholipase C, and thromboxane A2.{33367} MN-001 is reported to produce antifibrotic and anti-inflammatory activity in multiple preclinical models and is undergoing clinical investigations for use in the treatment of patients with either idiopathic pulmonary fibrosis or non-alcoholic steatohepatitis.{33367,33366}  

 

Available on backorder

SKU: 11948 - 500 µg Category:

Description

An antifibrotic and anti-inflammatory agent whose mechanisms of action include inhibition of eosinophil migration, antagonism of leukotriene receptors, inhibition of phosphodiesterases 3 and 4, as well as inhibition of 5-lipoxygenase, phospholipase C, and thromboxane A2; produces antifibrotic and anti-inflammatory activity in multiple animal models,


Formal name: 4-[6-acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]-butanoic acid

Synonyms:  KCA 757|Tipelukast

Molecular weight: 530.7

CAS: 125961-82-2

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Product Type|Biochemicals|Small Molecule Inhibitors|Phosphodiesterases||Product Type|Biochemicals|Small Molecule Inhibitors|Phospholipases||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Leukotrienes||Research Area|Immunology & Inflammation|Innate Immunity